Welcome to our dedicated page for Medpace Holdings news (Ticker: MEDP), a resource for investors and traders seeking the latest updates and insights on Medpace Holdings stock.
Medpace Holdings, Inc. (symbol: MEDP) is a leader in research-based drug development, renowned for its therapeutically focused approach. As a full-service global clinical research organization (CRO), Medpace partners strategically with select sponsors to streamline the path to drug approval, ensuring efficiency and cost-effectiveness. Headquartered in Cincinnati, the company extends its operations across six continents, encompassing Europe, Asia, South America, Africa, and Australia. With a workforce exceeding 5,400 employees spread across 40 countries, Medpace delivers customized solutions to both small and midsize biotechnology firms, as well as full-service offerings for global pharmaceutical companies.
Founded over 30 years ago, Medpace leverages its extensive medical and regulatory expertise to offer strategic insights and efficiencies at every phase of clinical trials. The company’s comprehensive services include bioanalytical laboratory services and advanced imaging capabilities, aimed at supporting the complex demands of drug development. Medpace’s commitment to high-quality service positions it as a steward of its clients’ drugs, from early-stage development through to final approval.
In 2014, Medpace was acquired by Cinven, a global private equity firm, for $915 million, with Cinven ending its investment in 2018. Despite this change in ownership, Medpace's dedication to advancing medical research and drug development remains steadfast. The company continues to forge strong partnerships and deliver superior results tailored to the unique needs of its clients.
Medpace Holdings reported a 27.3% increase in revenue for Q1 2022, reaching $330.9 million, up from $260.0 million in Q1 2021. The company achieved net new business awards of $423.0 million, resulting in a net book-to-bill ratio of 1.28x. GAAP net income rose to $61.3 million ($1.69 per diluted share), compared to $43.3 million ($1.14 per diluted share) last year. EBITDA increased by 31.3% to $70.4 million, with a margin of 21.3%. The firm forecasts 2022 revenue between $1.400 billion and $1.460 billion.
Medpace (MEDP), a clinical research organization, has partnered with Matthew 25: Ministries to support humanitarian efforts in Ukraine. The organization donated over
Medpace Holdings, Inc. (NASDAQ: MEDP) will release its first quarter 2022 financial results on April 25, 2022, after market close. A conference call is scheduled for April 26, 2022, at 9:00 a.m. ET to discuss the results. Interested participants can join by dialing 800-219-7113 (domestic) or 574-990-1030 (international) with passcode 3191816, or access the call via webcast on Medpace’s website. The call will be available for replay until May 3, 2022.
Medpace Holdings, Inc. (MEDP) reported a revenue increase of 18.8% to $308.6 million for Q4 2021, compared to $259.7 million in Q4 2020. For the full year 2021, revenue rose 23.4% to $1,142.4 million. The company secured $458.7 million in net new business awards for Q4 2021, up 27.9%, leading to a book-to-bill ratio of 1.49x. However, Q4 GAAP net income decreased slightly to $50.0 million from $50.9 million in the previous year. Full-year net income was $181.8 million. Medpace forecasts 2022 revenue between $1.400 billion and $1.460 billion.
Medpace Holdings, Inc. (Nasdaq: MEDP) will release its fourth quarter and fiscal year 2021 financial results after market close on February 14, 2022. A conference call is scheduled for February 15, 2022, at 9:00 a.m. ET to discuss the results. Interested parties can participate by dialing 800-219-7113 (domestic) or 574-990-1030 (international) using passcode 9164466. The call will be accessible via webcast on the company's website, with a replay available until February 22, 2022.
Medpace Holdings, Inc. (Nasdaq: MEDP) reported a 28.3% increase in revenue for Q3 2021, reaching $295.6 million, compared to $230.4 million in Q3 2020. Net new business awards also rose by 29.4% to $408.0 million, leading to a net book-to-bill ratio of 1.38x. GAAP net income was $48.6 million, or $1.29 per diluted share, reflecting a net income margin of 16.4%. The company forecasts 2021 revenue of $1.135 billion to $1.145 billion and 2022 revenue of $1.400 billion to $1.460 billion.
Medpace Holdings, Inc. (NASDAQ: MEDP) announced it will report its third quarter 2021 financial results after market close on October 25, 2021. A conference call to discuss these results is scheduled for October 26, 2021, at 9:00 a.m. ET. Participants can join by dialing 800-219-7113 (domestic) or 574-990-1030 (international) using passcode 5177474. The call will also be accessible via webcast on Medpace's investor website, with a replay available until November 2, 2021.
Medpace Holdings (Nasdaq: MEDP) will present at Baird’s Global Healthcare Conference on
Medpace is a global clinical contract research organization providing comprehensive clinical development services across various therapeutic areas, employing around 4,100 people in 40 countries.
Medpace Holdings, Inc. (Nasdaq: MEDP) reported a 35.8% increase in revenue for Q2 2021, reaching $278.3 million. The company's backlog grew 29.8% to $1.7 billion, and net new business awards hit $387.6 million, yielding a book-to-bill ratio of 1.39x. GAAP net income rose to $39.9 million or $1.06 per diluted share, representing a net income margin of 14.3%. The company forecasts 2021 revenue between $1.110 billion and $1.150 billion and GAAP net income between $162.5 million and $169.5 million.
Medpace Holdings, Inc. (Nasdaq: MEDP) announced the appointments of Jesse Geiger as president and Kevin Brady as chief financial officer, effective August 1, 2021. Geiger, who has been with Medpace since 2007 and previously served as CFO, will focus on driving growth while maintaining strategic oversight. Brady, appointed CFO, has been the executive director of finance since 2018. Both appointments aim to strengthen leadership as Medpace accelerates the global development of medical therapeutics.
FAQ
What is the current stock price of Medpace Holdings (MEDP)?
What is the market cap of Medpace Holdings (MEDP)?
What services does Medpace Holdings, Inc. provide?
Where is Medpace Holdings, Inc. headquartered?
How many employees does Medpace have?
In how many countries does Medpace operate?
When was Medpace founded?
Who acquired Medpace in 2014?
Does Medpace focus on any specific industries?
What expertise does Medpace bring to its partnerships?
Did Cinven exit its investment in Medpace?
What is Medpace's approach to drug development?
